User login
Key clinical point: In patients with moderate to severe psoriatic arthritis (PsA), risankizumab demonstrated superior efficacy vs placebo in improving disease activity outcomes with a favorable safety profile.
Major finding: A significantly higher number of patients receiving risankizumab vs placebo achieved more than 20% improvement in American College of Rheumatology score at week 24 (risk ratio [RR] 1.760; P < .001) and higher minimal disease activity response (RR 1.827; P < .05). The incidences of serious adverse events and serious treatment-emergent adverse events were similar between the risankizumab and placebo groups (P = .31 and P = .97, respectively).
Study details: This meta-analysis of six randomized controlled trials included 5038 patients with PsA who received either risankizumab or placebo.
Disclosures: This study was supported by grants from the National Natural Science Foundation of China and the Natural Science Foundation of Shanxi Province. The authors declared no conflicts of interest.
Source: Su QY, Zhou HN, Xia GM, et al. Efficacy and safety of risankizumab in patients with psoriatic arthritis: A systematic review and meta-analysis of randomized controlled trials. Rheumatol Ther. 2024 (Feb 1). doi: 10.1007/s40744-024-00638-5 Source
Key clinical point: In patients with moderate to severe psoriatic arthritis (PsA), risankizumab demonstrated superior efficacy vs placebo in improving disease activity outcomes with a favorable safety profile.
Major finding: A significantly higher number of patients receiving risankizumab vs placebo achieved more than 20% improvement in American College of Rheumatology score at week 24 (risk ratio [RR] 1.760; P < .001) and higher minimal disease activity response (RR 1.827; P < .05). The incidences of serious adverse events and serious treatment-emergent adverse events were similar between the risankizumab and placebo groups (P = .31 and P = .97, respectively).
Study details: This meta-analysis of six randomized controlled trials included 5038 patients with PsA who received either risankizumab or placebo.
Disclosures: This study was supported by grants from the National Natural Science Foundation of China and the Natural Science Foundation of Shanxi Province. The authors declared no conflicts of interest.
Source: Su QY, Zhou HN, Xia GM, et al. Efficacy and safety of risankizumab in patients with psoriatic arthritis: A systematic review and meta-analysis of randomized controlled trials. Rheumatol Ther. 2024 (Feb 1). doi: 10.1007/s40744-024-00638-5 Source
Key clinical point: In patients with moderate to severe psoriatic arthritis (PsA), risankizumab demonstrated superior efficacy vs placebo in improving disease activity outcomes with a favorable safety profile.
Major finding: A significantly higher number of patients receiving risankizumab vs placebo achieved more than 20% improvement in American College of Rheumatology score at week 24 (risk ratio [RR] 1.760; P < .001) and higher minimal disease activity response (RR 1.827; P < .05). The incidences of serious adverse events and serious treatment-emergent adverse events were similar between the risankizumab and placebo groups (P = .31 and P = .97, respectively).
Study details: This meta-analysis of six randomized controlled trials included 5038 patients with PsA who received either risankizumab or placebo.
Disclosures: This study was supported by grants from the National Natural Science Foundation of China and the Natural Science Foundation of Shanxi Province. The authors declared no conflicts of interest.
Source: Su QY, Zhou HN, Xia GM, et al. Efficacy and safety of risankizumab in patients with psoriatic arthritis: A systematic review and meta-analysis of randomized controlled trials. Rheumatol Ther. 2024 (Feb 1). doi: 10.1007/s40744-024-00638-5 Source